Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Summary: Novartis and Ono lead the wave of significant M&A activities in the biotech industry.
Throughout 2024, M&A activities in the pharma and biotech sectors have surged. Novartis has acquired TuHURA Biosciences, focusing on immuno-oncology therapies, strengthening its position in this field. These large-scale M&As drive innovation and growth in the biotech industry.
Summary: Global biotech companies form partnerships to accelerate advancements in oncology, metabolic diseases, and more.
Biotech companies are entering various partnerships to develop innovative treatments. For example, in September 2024, Eli Lilly partnered with Switzerland’s HAYA Therapeutics to explore genome targets for metabolic diseases, with potential milestone payments of up to $1 billion. These collaborations drive progress in medical research and development.
Summary: M&A activities in the biotech sector are on the rise, promoting the development of innovative therapies.
The 2024 biotech M&A market is experiencing growth with increased acquisitions valued at over $50 million. These deals are accelerating drug development and market expansion across various therapeutic areas, contributing to the industry’s advancement.
Summary: Investment in the biotech sector reaches its highest level in three years, signaling optimism in the industry.
According to Jefferies, biotech companies’ fundraising through stock issuance reached approximately $10 billion by Q3 2024, marking a three-year high. This trend indicates a resurgence of investor confidence and capital inflow into the biotech sector, fueling future growth.
Summary: Major biotech companies achieve significant milestones in clinical trials, advancing innovative therapies.
As of September 2024, several biotech companies have reported promising clinical trial outcomes, particularly in fields like oncology and gene therapy. These successes mark significant progress toward new drug approvals and commercialization.
@ 2024 . All rights reserved
@ 2024 . All rights reserved
